---
title: "Healthcare Divergence: Curia Restructures Over USD 1B Debt as Genmab Preps Late-Stage Oncology Pipeline"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296595187.md"
description: "Curia Global (CURX.US) is actively restructuring over USD 1 billion in private credit debt to ease liquidity strain, while biotech Genmab (GMAB.US) shifts focus to upcoming Q4 2026 Phase III clinical readouts for its oncology portfolio."
datetime: "2026-08-21T09:17:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296595187.md)
  - [en](https://longbridge.com/en/news/296595187.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296595187.md)
generator: "portal-rs"
---

# Healthcare Divergence: Curia Restructures Over USD 1B Debt as Genmab Preps Late-Stage Oncology Pipeline

The US healthcare sector is currently split between balance sheet engineering and clinical pipeline execution. Contract manufacturer Curia Global (CURX.US) is navigating a complex recapitalization process, while biotechnology company Genmab (GMAB.US) gears up for a critical stretch of late-stage data readouts.

Liquidity constraints have forced Curia into active restructuring mode. In July 2026, the CDMO announced a recapitalization agreement with financial stakeholders. This follows earlier reports in May of out-of-court restructuring talks with private credit lenders covering more than USD 1 billion in debt, including a USD 1.3 billion Apollo-led term loan and a USD 300 million second-lien facility provided by KKR. The financial overhaul runs parallel to a geographic footprint consolidation. Curia shuttered its Burlington, Massachusetts drug development facility in early 2026, cutting 81 jobs, while reallocating capital to upgrade its Valladolid sterile suite and expand its Glasgow cell line development platform. Shares have seen heightened volatility amid the ongoing debt negotiations.

For Genmab, the operational focus is squarely on commercializing its oncology pipeline. After reporting first-half financials in August 2026, the company is preparing for a data-heavy fourth quarter. Phase III trial results for Epkinly, rinatabart sesutecan (Rina-S), and petosemtamab are expected by year-end, which will be crucial for supporting potential 2027 product launches. The readouts represent a pivotal transition as Genmab prepares to market its first wholly-owned antibody-drug conjugates and bispecific antibodies. The stock's recent performance has been largely dictated by expectations surrounding these late-stage pipeline developments.

*This article does not constitute investment advice.*

### Related Stocks

- [CURX.US](https://longbridge.com/en/quote/CURX.US.md)
- [GMAB.US](https://longbridge.com/en/quote/GMAB.US.md)

## Related News & Research

- [Curanex Pharmaceuticals Inc Q2 2026: Net income $(3.29M), EPS $(0.12) — 10-Q Summary](https://longbridge.com/en/news/295957896.md)
- [Genmab Updates Articles of Association, Expands Capital-Raising Flexibility](https://longbridge.com/en/news/295678408.md)
- [Capital Increase in Genmab as a Result of Employee Warrant Exercise](https://longbridge.com/en/news/295566458.md)
- [Avidity Partners Management LP Cuts Stock Holdings in Genmab A/S Sponsored ADR $GMAB](https://longbridge.com/en/news/294575607.md)
- [Weekly Recap: Epcoritamab‑lenalidomide PFS success and 2026 royalties rise](https://longbridge.com/en/news/295360680.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**